RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Alcohol Liver Disease
Interventions
DRUG:
Pemvidutide
OTHER:
Placebo
Sponsor
Altimmune, Inc.